Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323668 | 1.00 | TSHR (0.51) | TSHRCA1CA2LMNAMAPT | |
| SCHEMBL9699519 | 0.97 | TSHR (0.50) | TSHRCA1CA2LMNAMAPT | |
| SCHEMBL6601053 | 0.87 | MAPT (0.48) | MAPTHPGDMEN1KMT2AKDM4E | |
| SCHEMBL11607523 | 0.86 | CA1 (0.47) | TSHRCA1CA2LMNAMAPT | |
| Dimethyl Sulfone SCHEMBL8750580 | 0.86 | TSHR (0.60) | TSHRCA1CA2HTR2CHTR2B | |
| SCHEMBL29011009 | 0.85 | TSHR (0.50) | TSHRHTR2CHTR2BHPGDKDM4E | |
| SCHEMBL630517 | 0.85 | TSHR (0.63) | TSHRHTR2CHTR2BFKBP1AELANE | |
| SCHEMBL693351 | 0.85 | TSHR (0.63) | TSHRHTR2CHTR2BFKBP1AELANE | |
| SCHEMBL4069956 | 0.85 | TSHR (0.63) | TSHRHTR2CHTR2BFKBP1AELANE | |
| Hydrochloric Acid SCHEMBL630516 | 0.83 | TSHR (0.65) | TSHRHTR2CHTR2BFKBP1AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8057810-B2 | Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application | Obschestvo S Ogranichennoi Otvetstvennostyu “SIA Peptides” (RU) | 2011-11-15 | — | — | US | disclosed |
| EP-2032595-B1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU SIA PEPTIDES (RU) | 2011-06-22 | — | — | EP | disclosed |
| US-20090170785-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU 'SIA PEPTIDES' (RU) | 2009-07-02 | — | — | US | disclosed |
| EP-2032595-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007139435-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSVENNOSTYU 'SIA PEPTIDES' (RU) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170785-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | VIP, ARGLU1, ARG1 | TSHR 4042/4885CA1 3457/4885CA2 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.